Masimo (MASI -0.9%) is giving COVID-19-rattled healthcare investors a ray of hope with its preliminary Q1 results.
Product sales should be $265M – 271M, above
consensus of ~$252M, although management says it will not provide
guidance this year.
Consensus EPS for the quarter is $0.87.
Final results will be released on Tuesday, April 28, after the close.
https://seekingalpha.com/news/3557221-masimo-sees-q1-sales-growth-above-consensus
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.